Capstone Therapeutics Corp (CAPS) financial statements (2021 and earlier)

Company profile

Business Address 1275 WEST WASHINGTON STREET
TEMPE, AZ 85281
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0112211
Cash and cash equivalents0112211
Other current assets0000000
Total current assets:1112211
Noncurrent Assets
Long-term investments and receivables66     
Long-term investments66     
Intangible assets, net (including goodwill)  00000
Intangible assets, net (excluding goodwill)  00000
Other undisclosed noncurrent assets(6)(6)     
Total noncurrent assets:  00000
TOTAL ASSETS:1112212
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1100000
Accounts payable1100000
Accrued liabilities0000000
Total current liabilities:1100000
Noncurrent Liabilities
Long-term debt and lease obligation3322222
Long-term debt, excluding current maturities3322222
Total noncurrent liabilities:3322222
Total liabilities:3333332
Stockholders' equity
Stockholders' equity attributable to parent(3)(2)(1)(1)(0)(1)(1)
Common stock0000000
Additional paid in capital190190190190190190190
Accumulated deficit(193)(193)(192)(191)(191)(192)(191)
Total stockholders' equity:(3)(2)(1)(1)(0)(1)(1)
TOTAL LIABILITIES AND EQUITY:1112212

Income statement (P&L) ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Gross profit:  (4) 2  
Operating expenses(1)(1)(0)(1)(1)(1)(1)
Other undisclosed operating income  4    
Operating income (loss):(1)(1)0(1)1(1)(1)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)0(0)(0)(0)(0)
Income (loss) from continuing operations before income taxes:(1)(1)0(1)1(1)(1)
Income tax expense (benefit) (0)(0)  00
Net income (loss) available to common stockholders, diluted:(1)(1)0(1)1(1)(1)

Comprehensive Income ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Net income (loss):(1)(1)0(1)1(1)(1)
Comprehensive income (loss), net of tax, attributable to parent:(1)(1)0(1)1(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: